Screen Them All: High-Throughput Pan-Cancer Genetic and Phenotypic Biomarker Screening from H&E Whole Slide Images

Fuente: arXiv
Enregistré dans:
Détails bibliographiques
Auteurs principaux: Wang, Yi Kan, Tydlitatova, Ludmila, Kunz, Jeremy D., Oakley, Gerard, Chow, Bonnie Kar Bo, Godrich, Ran A., Lee, Matthew C. H., Aghdam, Hamed, Bozkurt, Alican, Zelechowski, Michal, Vanderbilt, Chad, Kanan, Christopher, Retamero, Juan A., Hamilton, Peter, Yousfi, Razik, Fuchs, Thomas J., Klimstra, David S., Liu, Siqi
Format: Preprint
Publié: 2024
Sujets:
Accès en ligne:
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
_version_ 1866911053143605248
author Wang, Yi Kan
Tydlitatova, Ludmila
Kunz, Jeremy D.
Oakley, Gerard
Chow, Bonnie Kar Bo
Godrich, Ran A.
Lee, Matthew C. H.
Aghdam, Hamed
Bozkurt, Alican
Zelechowski, Michal
Vanderbilt, Chad
Kanan, Christopher
Retamero, Juan A.
Hamilton, Peter
Yousfi, Razik
Fuchs, Thomas J.
Klimstra, David S.
Liu, Siqi
author_facet Wang, Yi Kan
Tydlitatova, Ludmila
Kunz, Jeremy D.
Oakley, Gerard
Chow, Bonnie Kar Bo
Godrich, Ran A.
Lee, Matthew C. H.
Aghdam, Hamed
Bozkurt, Alican
Zelechowski, Michal
Vanderbilt, Chad
Kanan, Christopher
Retamero, Juan A.
Hamilton, Peter
Yousfi, Razik
Fuchs, Thomas J.
Klimstra, David S.
Liu, Siqi
contents Molecular assays are standard of care for detecting genomic alterations in cancer prognosis and therapy selection but are costly, tissue-destructive and time-consuming. Artificial intelligence (AI) applied to routine hematoxylin and eosin (H&E)-stained whole slide images (WSIs) offers a fast and economical alternative for screening molecular biomarkers. We introduce OmniScreen, a high-throughput AI-based system leveraging Virchow2 embeddings extracted from 60,529 cancer patients with paired 489-gene MSK-IMPACT targeted biomarker panel and WSIs. Unlike conventional approaches that train separate models for each biomarker, OmniScreen employs a unified model to predict a broad range of clinically relevant biomarkers across cancers, including low-prevalence targets impractical to model individually. OmniScreen reliably identifies therapeutic targets and shared phenotypic features across common and rare tumors. We investigate the biomarker prediction probabilities and accuracies of OmniScreen in relation to tumor area, cohort size, histologic subtype alignment, and pathway-level morphological patterns. These findings underscore the potential of OmniScreen for routine clinical screening.
format Preprint
id arxiv_https___arxiv_org_abs_2408_09554
institution arXiv
publishDate 2024
record_format arxiv
spellingShingle Screen Them All: High-Throughput Pan-Cancer Genetic and Phenotypic Biomarker Screening from H&E Whole Slide Images
Wang, Yi Kan
Tydlitatova, Ludmila
Kunz, Jeremy D.
Oakley, Gerard
Chow, Bonnie Kar Bo
Godrich, Ran A.
Lee, Matthew C. H.
Aghdam, Hamed
Bozkurt, Alican
Zelechowski, Michal
Vanderbilt, Chad
Kanan, Christopher
Retamero, Juan A.
Hamilton, Peter
Yousfi, Razik
Fuchs, Thomas J.
Klimstra, David S.
Liu, Siqi
Quantitative Methods
Computer Vision and Pattern Recognition
Image and Video Processing
Molecular assays are standard of care for detecting genomic alterations in cancer prognosis and therapy selection but are costly, tissue-destructive and time-consuming. Artificial intelligence (AI) applied to routine hematoxylin and eosin (H&E)-stained whole slide images (WSIs) offers a fast and economical alternative for screening molecular biomarkers. We introduce OmniScreen, a high-throughput AI-based system leveraging Virchow2 embeddings extracted from 60,529 cancer patients with paired 489-gene MSK-IMPACT targeted biomarker panel and WSIs. Unlike conventional approaches that train separate models for each biomarker, OmniScreen employs a unified model to predict a broad range of clinically relevant biomarkers across cancers, including low-prevalence targets impractical to model individually. OmniScreen reliably identifies therapeutic targets and shared phenotypic features across common and rare tumors. We investigate the biomarker prediction probabilities and accuracies of OmniScreen in relation to tumor area, cohort size, histologic subtype alignment, and pathway-level morphological patterns. These findings underscore the potential of OmniScreen for routine clinical screening.
title Screen Them All: High-Throughput Pan-Cancer Genetic and Phenotypic Biomarker Screening from H&E Whole Slide Images
topic Quantitative Methods
Computer Vision and Pattern Recognition
Image and Video Processing
url https://arxiv.org/abs/2408.09554